ジヨードヒドロキシキノリン
- 関
- iodoquinol
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2015/11/18 05:17:47」(JST)
[Wiki en表示]
Diiodohydroxyquinoline
|
|
Names |
IUPAC name
5,7-diiodoquinolin-8-ol
|
Other names
Diquinol, iodoxin, diiodoquin, amebaquin
|
Identifiers |
CAS Number
|
83-73-8 Y |
ATC code |
G01AC01 |
ChEMBL |
ChEMBL86754 N |
ChemSpider |
3597 N |
InChI
-
InChI=1S/C9H5I2NO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H N
Key: UXZFQZANDVDGMM-UHFFFAOYSA-N N
-
InChI=1/C9H5I2NO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H
Key: UXZFQZANDVDGMM-UHFFFAOYAF
|
Jmol interactive 3D |
Image |
KEGG |
D00581 Y |
MeSH |
Iodoquinol |
PubChem |
3728 |
SMILES
-
C1=CC2=C(C(=C(C=C2I)I)O)N=C1
|
UNII |
63W7IE88K8 Y |
Properties |
Chemical formula
|
C9H5I2NO |
Molar mass |
396.951 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
N verify (what is YN ?) |
Infobox references |
|
|
The quinoline derivative diiodohydroxyquinoline (INN) or iodoquinol (USAN), can be used in the treatment of amoebiasis.[1]
It is poorly absorbed from the gastrointestinal tract and is used as a luminal amebicide. It acts by chelation of ferrous ions essential for metabolism.[2]
It was discovered by Adco Co. and introduced as diiodohydroxyquinoline.[3]
Susceptibility of Dientamoeba fragilis has been measured.[4]
Iodoquinol is an amebocide used against Entamoeba histolytica, and it is active against both cyst and trophozoites that are localized in the lumen of the intestine. It is considered the drug of choice for treating asymptomatic or moderate forms of amebiasis. The mechanism of action is unknown. Iodoquinol is used for diseases caused by moderate intestinal amebiasis.
References
- ^ Ghaskadbi S, Vaidya VG (March 1989). "In vivo antimutagenic effect of ascorbic acid against mutagenicity of the common antiamebic drug diiodohydroxyquinoline". Mutat. Res. 222 (3): 219–22. doi:10.1016/0165-1218(89)90137-7. PMID 2493578.
- ^ Gideon Online http://web.gideononline.com/web/therapy/index.php?type=drugs&code=20130&view=General.
- ^ Page 1312. http://books.google.co.in/books?id=TIu28TH_iAYC&printsec=frontcover&source=gbs_ge_summary_r&cad=0#v=onepage&q&f=false
- ^ Chan FT, Guan MX, Mackenzie AM, Diaz-Mitoma F (May 1994). "Susceptibility testing of Dientamoeba fragilis ATCC 30948 with iodoquinol, paromomycin, tetracycline, and metronidazole". Antimicrob. Agents Chemother. 38 (5): 1157–60. doi:10.1128/aac.38.5.1157. PMC 188168. PMID 8067755.
Antiparasitics – antiprotozoal agents – agents against amoebozoa/amebicide (P01)
|
|
Entamoeba |
Tissue amebicides
|
Nitroimidazole derivatives
|
- Metronidazole#
- Tinidazole
- Ornidazole
- Nimorazole
- Secnidazole
- Azanidazole
- Propenidazole
|
|
Other
|
- isoquinoline (Emetine/Dehydroemetine)
|
|
|
Luminal amebicides
|
Hydroxyquinoline derivatives
|
- Cl (Chlorquinaldol)
- Br (Tilbroquinol
- Broxyquinoline)
- I (Diiodohydroxyquinoline)
- I, Cl (Clioquinol)
|
|
Dichloroacetamide derivatives
|
- Diloxanide#
- Clefamide
- Etofamide
- Teclozan
|
|
Aminoglycoside
|
|
|
|
Other/ungrouped
|
- arsenic (Arsthinol
- Difetarsone
- Glycobiarsol)
- phenanthroline (Phanquinone)
- aminoacridine (Mepacrine)
- quinazoline (Trimetrexate)
- thiazole (Tenonitrozole)
- sesquiterpene (Fumagillin)
|
|
|
Acanthamoeba |
- Propamidine
- Chlorhexidine
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
Index of protozoan infection
|
|
Description |
- Alveolata
- Amoebozoa
- Excavata
- Protist
|
|
Disease |
- Amoebozoa
- Chromalveolate
- Excavata
|
|
Treatment |
- Drugs
- amoeboa
- chromalveolate
- excavata
|
|
|
Antiparasitics – antiprotozoal agents – Excavata antiparasitics (P01)
|
|
Discicristata |
Trypanosomiasis
|
- African trypanosomiasis: ornithine (Eflornithine#)
- arsenical (Melarsoprol#)
- benzamidine (Pentamidine#)
- naphthalenesulfonate (Suramin#)
Chagas disease: nitroimidazole (Benznidazole#)
|
|
Leishmaniasis
|
- macrolide (Amphotericin B#)
Pentavalent antimonials (Meglumine antimoniate#, Sodium stibogluconate)
- benzamidine (Pentamidine#)
- phosphorylcholine (Miltefosine)
- neomycin (Paromomycin)
|
|
PAM
|
- macrolide (Amphotericin B)
|
|
|
Trichozoa |
Giardiasis
|
- nitroimidazole (Metronidazole#, Tinidazole)
- benzimidazole (Albendazole)
- thiazole (Nitazoxanide)
- nitrofuran (Furazolidone)
- aminoacridine (Quinacrine)
|
|
Trichomoniasis
|
- nitroimidazole (Carnidazole, Metronidazole#, Tinidazole)
|
|
Dientamoebiasis
|
- nitroimidazole (Metronidazole
- Secnidazole)
- oxyquinoline (Iodoquinol)
- tetracycline (Doxycycline)
- neomycin (Paromomycin)
|
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
Index of protozoan infection
|
|
Description |
- Alveolata
- Amoebozoa
- Excavata
- Protist
|
|
Disease |
- Amoebozoa
- Chromalveolate
- Excavata
|
|
Treatment |
- Drugs
- amoeboa
- chromalveolate
- excavata
|
|
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Treatment failure in patients with chronic Blastocystis infection.
- Roberts T1, Ellis J, Harkness J, Marriott D, Stark D.
- Journal of medical microbiology.J Med Microbiol.2014 Feb;63(Pt 2):252-7. doi: 10.1099/jmm.0.065508-0. Epub 2013 Nov 15.
- This article reports long-term infection and treatment failure in 18 symptomatic individuals infected with Blastocystis spp. Patients were initially treated with either metronidazole, iodoquinol or triple combination therapy consisting of nitazoxanide, furazolidone and secnidazole. Following treatme
- PMID 24243286
- Chromatographic methods for simultaneous determination of diiodohydroxyquinoline and metronidazole in their binary mixture.
- Ali NW1, Gamal M, Abdelkawy M.
- Pakistan journal of pharmaceutical sciences.Pak J Pharm Sci.2013 Sep;26(5):865-71.
- Two chromatographic methods were developed for analysis ofdiiodohydroxyquinoline (DIHQ) and metronidazole (MTN). In the first method, diiodohydroxyquinoline and metronidazole were separated on TLC silica gel 60F254 plate using chloroform: acetone: glacial acetic acid (7.5: 2.5: 0.1, by volume) as mo
- PMID 24035940
- Marie C1, Petri WA Jr.
- BMJ clinical evidence.BMJ Clin Evid.2013 Aug 30;2013. pii: 0918.
- INTRODUCTION: Amoebic dysentery is caused by the protozoan parasite Entamoeba histolytica. It is transmitted in areas where poor sanitation allows contamination of drinking water and food with faeces. In these areas, up to 40% of people with diarrhoea may have amoebic dysentery.METHODS AND OUTCOMES:
- PMID 23991750
Related Links
- Diiodohydroxyquinoline (INN) or iodoquinol (USAN), widely known by the trade name Diodoquin, is a quinoline ... "In vivo antimutagenic effect of ascorbic acid against mutagenicity of the common antiamebic drug diiodohydroxyquinoline".
- 1 Feb 2012 ... Diiodohydroxyquinoline information including symptoms, causes, diseases, symptoms, treatments, and other medical and health issues.
Related Pictures
★リンクテーブル★
[★]
- 英
- diiodohydroxyquinoline
- 関
- ヨードキノール